Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Next Previous
Trial Profile

An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emricasan (Primary)
  • Indications Liver cirrhosis; Portal hypertension
  • Focus Therapeutic Use
  • Sponsors Conatus Pharmaceuticals

Most Recent Events

  • 31 Jul 2018 Exploratory results assessing whether emricasan lowers PH in patients with compensated cirrhosis published in the Hepatology
  • 03 Feb 2016 According to a Conatus Pharmaceuticals media release, the US FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), based on data from this trial.
  • 14 Nov 2015 Results will be presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), according to a Conatus Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top